A photopharmaceutical drug to treat psoriasis and avoid adverse effects The UB team has characterized the new compound MRS7787, a light-activatable molecule that binds to the A3 adenosine receptor ...

which is in a phase 3 clinical trial to treat rheumatoid arthritis and psoriasis. The team now also wants to validate this new drug target in other inflammatory conditions—such as arthritis or ...

A photopharmaceutical drug to treat psoriasis and avoid adverse effects The UB team has characterized the new compound MRS7787, a light-activatable molecule that binds to the A3 adenosine receptor ...

BI 655130, a new biological entity, has already shown “remarkable efficacy” in early clinical testing with a single dose in patients affected by generalised pustular psoriasis. Results support ...

The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...